My watch list  

Ultra-sensitive Biomarker Quantification in Microsampling Support

New perspectives in analyte quantification by fine-tuning between sensitivity and sample consumption

Christian Pieper, PhD
Chimera Biotec GmbH

Imperacer® Technology: Due to exponential signal amplification during Immuno-PCR (IPCR) ultra-sensitive biomarker quantification is feasible.

Imperacer® enables fine-balance between required assay sensitivity and available sample consumption at given acceptance criteria. Due to exponential signal amplification the assay tolerates high sample dilutions.

Biomarker quantification in microsampling support is an emerging field in pre-clinical studies. While sample volumes of 10 µl may be sufficient for PK studies to determine drug concentration in ng/ml range, multiparameter quantification of low abundant endogenous biomarker (typically low pg/ml range) in ligand-binding assay (LBA) microsampling support is challenging. A major hurdle is the correlation of required sample volume vs. assay sensitivity on most immune-assay platforms. Due to exponential signal amplification, Imperacer® Immuno-PCR (IPCR) technology enables ultra-sensitive biomarker determination in microsampling support with excellent sensitivities at low per-run sample-consumption. Furthermore, Imperacer® enables fine-tuning of required sensitivity vs. sample volume towards the needs of specific study support. Here we utilized Imperacer® Immuno-PCR (IPCR) for quantification of low abundant biomarker in sub pg/ml range with less than 10 µl total sample consumption in duplicate runs.

You can download the complete white paper as a PDF file

Facts, background information, dossiers
  • microsampling
More about Chimera Biotec
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE